Clinical effects of ischemic preconditioning

Current Opinion in Cardiology

Volumn 14, Issue 4, 1999, Pages 340-348

  Schwarz, Ernst R ^a,b   Reffelmann, Thorsten ^b   Kloner, Robert A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR STIMULATING AGENT; POTASSIUM CHANNEL STIMULATING AGENT; SULFONYLUREA;

ACUTE HEART INFARCTION; ANGINA PECTORIS; BALLOON; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; HEART INFARCTION PREVENTION; HEART INFARCTION SIZE; HEART MUSCLE; HEART PROTECTION; HEART SURGERY; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

CARDIOVASCULAR AGENTS; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION;

EID: 0032767503     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199907000-00010     Document Type: Review

References (98)

1. 1 Murry CE, Jennings RB, Reimer KA: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74:1124-1136.
2. 2 Schott RJ, Rohmann S, Braun E, Schaper W: Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res 1990, 66:1133-1142.
3. 3 Liu Y, Downey JM: Ischemic preconditioning protects against infarction in rat heart. Am J Physiol 1992, 263:1107-1112.
4. 4 Shiki, K, Hearse DJ: Preconditioning of ischemic myocardium: Reperfusion-induced arrhythmias. Am J Physiol 1987, 253:H1470-1476.
5. 5 Hagar JM, Hale SL, Kloner RA: Effect of preconditionig ischemia on reperfusion arrhythmias after coronary artery occlusion and reperfusion in the rat. Circ Res 1991, 68:61-68.
6. 6 Vegh A, Komori S, Szekeres L, Parrat JR: Arrhythmic effects of preconditioning in anesthetized dogs and rats. Cardiovasc Res 1992, 26:487-495.
7. 7 Cohen MV, Liu GS, Downey JM: Preconditioning causes improved wall motion as well as smaller infarcts after transient coronary occlusion tn rabbits. Circulation 1991, 84:341-349.
8. 8 Pryzyklenk K, Kloner RA: Ischemic preconditioning: exploring the paradox. Progr Cardiovasc Dis 1998, 40:517-547.
9. 9 Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P: Regional ischemic "preconditioning" protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation 1993, 87:893-899.
10. 10 Gho BCG, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD: Myocardial protection by brief ischemia in noncardiac tissue. Circulation 1996, 94:2193-2200.
11. 11 Birnbaum Y, Hale SH, Kloner RA: Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with pacing of the gastrocnemius muscle. Circulation 1997, 96:1641-1646.
12. 12 Schwarz ER, Whyte WS, Kloner RA: Ischemic preconditioning. Curr Opin Cardiol 1997, 12:475-481.
13. 13 Marber MS, Latchman DS, Walker JM, Yellon DM: Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction. Circulation 1993, 88:1264-1272.
14. 14 Kuzuya T, Hoshida S, Yamashita N, Fuji H, Oe H, Hori M, et al.: Delayed effects of sublethal ischemia on the acquisition of tolerance to ischemia. Circ Res 1993, 72:1293-1299.
15. 15 Li YW, Whittaker P, Kloner RA: The transient nature of the effect of ischemic preconditioning on myocardial infarct size and ventricular arrhythmia. Am Heart J 1992, 123:346-353.
16. 16 Murry CE, Richard VJ, Jennings RB, Reimer KA: Myocardial protection is lost before contractile function recovers from ischemic preconditioning. Am J Physiol 1991, 260:H796-H804.
17. 17 Van Winkle DM, Thornton JD, Downey DM, Downey JM: The natural history of preconditioning: cardioprotection depends on duration of transient ischemia and time to subsequent ischemia. Coron Artery Dis 1991, 2:613-619.
18. 18 Yao Z, Gross GJ: A comparison of adenosine-induced cardioprotection and ischemic preconditioning in dogs: efficacy, time course, and role of ATP-sensitive potassium channels. Circulation 1994, 89:1229-1236.
19. 19 Schwarz ER, Fleischhauer J, Montino H, Chakupurakal R, Foresti M, Schuetz T, et al.: Infarct size reduction by ischemic preconditioning is a monophasic, short-lived phenomenon in anesthetized pigs. J Cardiovasc Pharmacol Ther 1998, 3:63-70.
20. 20 Simkhovich BZ, Przyklenk K, Kloner RA: Role of PKC as a cellular mediator of ischemic preconditioning: a critical review. Cardiovasc Res 1998, 40:9-22.
21. 21 Yellon DM, Alkuhulaifi AM, Pugsley WB: Preconditioning the human myocardium. Lancet 1993, 342:276-277.
22. 22 Kloner RA, Yellon DM: Does ischemic preconditioning occur in patients? J Am Coll Cardiol 1994, 24:1133-1142.
23. 23 Ikonomidis JS, Tumiati LC, Weisel RD, Mickle DAG, Li RK: Preconditioning human ventricular cardiomyocytes with brief periods of simulated ischaemia. Cardiovasc Res 1994, 28:1285-1291.
24. 24 Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW, Herrmann HC, Laskey WK: Adaptation to ischemia during percutaneous transluminal coronary angioplasty: clinical, hemodynamic, and metabolic features. Circulation 1990, 82:2044-2051.
25. 25 Kloner RA, Shook T, Przyklenk K, Davis VG, Junio L, Matthews R, et al. for the TIMI 4 Investigators: Previous angina alters in-hospital outcome in TIMI 4 A clinical correlate to preconditioning? Circulation 1995, 91:37-47.
26. 26 Kloner RA, Shook T, Antman EM, Cannon CP, Przyklenk K, Yoo K, et al.: Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B. Circulation 1998, 97:1042-1045.
27. 27 Ottani F, Galvani M, Ferrini D, Sorbello F, Limonetti P, Pantoli D, Rusticali F: Prodromal angina limits infarct size: a role for ischemic preconditioning. Circulation 1995, 91:291-297.
28. 28 Nakagawa Y, Ito H, Kitakaze M, Kusuoka H, Hori M, Kuzuya T, et al.: Effect of angina pectoris on myocardial protection in patients with reperfused anterior wall myocardial infarction: retrospective clinical evidence of "preconditioning". J Am Coll Cardiol 1995, 25:1076-1083.
29. 29 Napoli C, Liguori A, Chiarello M, di leso N, Condorelli M, Ambrosio G: New-onset angina preceding myocardial infarction is associated with improved contractile recovery after thrombolysis. Eur Heart J 1998, 19:411-419.
30. 30 Tamura K, Tsuji H, Nishiue T, Tokunaga S, Iwasaka T: Association of preceding angina with in-hospital life-threatening ventricular tachyarrhythmias and late potentials in patients with a first acute myocardial infarction. Am Heart J 1997, 133:297-301.
31. 31 Nagao K, Satou K, Arima K, Watanabe I, Yamashita M, Kanmatsuse K: Relationship between preinfarction angina and the time interval to reperfusion with thrombolytic therapy in acute myocardial infarction. Jpn Circ J 1997, 61:843-849.
32. 32 Abete P, Ferrara N, Cacciatore F, Madrid A, Bianco S, Calabrese C, et al.: Angina-induced protection against myocardial in adults and elederly patients: a loss of preconditioning mechanism in the aging heart? J Am Coll Cardiol 1997, 30:947-954.
33. 33 Kloner RA, Przyklenk K, Shook T, Cannon CP: Protection conferred by preinfarct angina is manifest in the aged heart: evidence from the TIMI-4 trial. Journal of Thrombosis & Thrombolysis 1998, 6:89-92.
34. 34 Dana A, Yellon DM: Cardioprotection by pre-infarct angina: is it ischaemic preconditioning? Eur Heart J 1998, 19:367-369.
35. 35 Cohen MV, Yang XM, Downey JM: Attenuation of S-T segment elevation during repetitive coronary occlusions truly reflects the protection of ischemic preconditioning and is not an epiphenomenon. Basic Res Cardiol 1997, 92:426-434.
36. 36 Lim R, Laskey WK: Ischemic preconditioning in unstable coronary syndromes: evidence for time dependence. J Am Coll Cardiol 1997, 30:1461-1465.
37. 37 Szmagala P, Morawiski W, Krejca M, Gburek T, Bochenek A: Evaluation of perioperative myocardial tissue damage in ischemically preconditioned human hearts during aorto coronary bypass surgery. J Cardiovasc Surg 1998, 39:791-795.
38. 38 Cremer J, Steinhoff G, Karck M, Ahnsell T, Brandt M, Teebken OE, et al.: Ischemic preconditioning before myocardial protection with cold blood cardioplegia in coronary surgery. Eur J Cardiothorac Surg 1997, 12:753-758.
39. 39 Lu EX, Chen SX, Yuan MD, Hu TH, Zhou HC, Luo WJ, et al.: Preconditioning improves myocardial preservation in patients undergoing open heart operations. Ann Thorac Surg 1997, 64:1320-1324.
40. 40 Zarro DL, Palanzo DA, Sadr FS: Myocardial preconditioning using adenosine: review and clinical experience. Perfusion 1998, 13:145-150.
41. 41 Cohen MV, Thornton JD, Thornton CS, Sato H, Miki T, Downey JM: Intravenous co-infusion of adenosine and norepinephrine preconditions the heart without adverse homodynamic effects. J Thorac Cardiovasc Surg 1997, 114:236-242.
42. 42 Latham P, Joshi GP: Coronary revascularisation without cardiopulmonary bypass: use of ischemic preconditioning and adenosine. Anesthesiology 1998, 88:828-830.
43. 43 Karck M, Rahmanian P, Maverick A: Ischemic preconditioning enhances donor heart preservation. Transplantation 1996, 62:17-22.
44. 44 Kirsch M, Baufreton C, Fernandez C, Brunet S, Pasteau F, Astier A, Loisance DY: Preconditioning with cromakalim improves long-term myocardial preservation for heart transplantation. Ann Thorac Surg 1998, 66:417-424.
45. 45 Landymore RW, Bayes AJ, Murphy JT, Fris JH: Preconditioning prevents myocardial stunning after cardiac transplantation. Ann Thorac Surg 1998, 66:1953-1957.
46. 46 Thornton JD, Liu GS, Olsson RA, Downey JM: Intravenous pretreatment with A1-selective adenosine analogues protects the heart against infarction. Circulation 1992, 85:659-665.
47. 47 Li Y, Kloner RA: The cardioprotective effects of ischemic "preconditioning" are not mediated by adenosine receptors in rat hearts. Circulation 1993, 87:1642-1648.
48. 48 Miura T, Tsuchida A: Adenosine and preconditioning revised. Clin Exp Pharmacol Physiol 1999, 26:92-99. The mechanism and signal pathway of adenosine in preconditioning are revised with respect to adenosine production, receptors, PKC activation, and opening of ATP-sensitive potassium channels.
49. 49 Edwards RJ, Marber MS: Myocardial preconditioning: mechanisms and man. Int J Clin Pract 1998, 52:395-401
50. 50 Meldrum DR, Cain BS, Cleveland JC Jr, Meng X, Ayala A, Banerjee A, Harken AH: Adenosine decreases post-ischaemic cardiac TNF-alpha production: anti-inflammatory implications for preconditioning and transplantation. Immunology 1997, 92:472-477.
51. 51 Vogt AM, Ando H, Arras M, Elasser A: Lack of adenosine causes myocardial refractoriness. J Am Coll Cardiol 1998, 31:1134-1141.
52. 52 Granger CB: Adenosine for myocardial protection in acute myocardial infarction. Am J Cardiol 1997, 79:44-48.
53. 53 Seiler C, Billinger M: Adenosine-induced preconditioning of human myocardium? Circulation 1998, 98:824-825.
54. 54 Lee HAT: Adenosine pretreatment of human myocardium and ischemic preconditioning. Circulation 1998, 97:2279.
55. 55 Kloner RA, Kay G: Intravenous co-infusion of adenosine and norepinephrine. J Thorac Cardiovasc Surg 1997, 114:234-235.
56. 56 Leesar MA, Stoddard M, Ahmed M, Broadbent J, Bolli R: Preconditioning of human myocardium with adenosine during coronary angioplasty. Circulation 1997, 95:2500-2507.
57. 57 Mehta AB, Merdikar HM, Hiregouder NS, Sethi RB, Solanki DR: Preconditioning the human myocardium with intracoronary adenosine. Indian Heart J 1998, 50:397-401.
58. 58 Munch Ellingsen J, Bugge E, Ytrehus K: Blockade of the KATP-channel by glibenclamide aggravates ischemic injury, and counteracts ischemic preconditioning. Basic Res Cardiol 1996, 91:382-388.
59. 59 Strauer BE, Heidland UE, Heintzen MP, Schwartzkopff B: Pharmacologic myocardial protection during percutaneous transluminal coronary angioplasty by intracoronary application of dipyridamole: impact on hemodynamic function and left ventricular performance. J Am Coll Cardiol 1996, 28:1119-1126.
60. 60 Sakata Y, Kodama K, Komamura K, Lim YJ, Ishikura F, Hirayama A, et al.: Salutary effect of adjunctive intracoronary nicorandil administration on restoration of myocardial blood flow and functional improvement in patients with acute myocardial infarction. Am Heart J 1997, 133:616-621.
61. 61 Tomai F, Crea F, Gaspardone A, Versaci F, De Pulis R, Poisca P, et al.: Effects of A1 adenosine receptor blockade by bamiphylline on ischaemic preconditioning during coronary angioplasty. Eur Heart J 1996, 17:846-853.
62. 62 Suzuki K, Miura T, Miki T, Tsuchida A, Shimamoto K: Infarct-size limitation by preconditioning is enhanced by dipyridamole administered before but not after preconditioning: evidence for the role of interstitial adenosine level during preconditioning as a primary determinant of cardioprotection. J Cardiovasc Pharmacol 1998, 31:1-9.
63. 63 Pasini FL. Guideri F, Ferber D, Galgano G, Bianchi A, Isidori S, et al.: Pharmacological preconditioning of ischemic heart disease by low-dose dipyridamole. Int J Cardiol 1996, 56:17-27.
64. 64 Yao Z, Mizumura T, Mei DA, Gross GJ: KATP channels and memory of ischemic preconditioning in dogs: synergism between adenosine and KATP channels. Am J Physiol 1997, 272:H334-H342.
65. 65 Speechly-Dick ME, Grover GJ, Yellon DM: Does ischemic preconditioning in the human heart involve protein kinase C and the ATP-dependent K+ channel? Circ Res 1995, 77:1030-1035.
66. 66 Carr CS, Yellon DM: Ischaemic preconditioning may abolish the protection afforded by ATP-sensitive potassium channel openers in isolated human atrial muscle. Basic Res Cardiol 1997, 92:252-260.
67. 67 Imagawa J, Baxter GF, Yellon DM: Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo. J Cardiovasc Pharmacol 1998, 31:74-79.
68. 68 Patel DJ, Purcell HJ, Fox KM: Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularisation. Eur Heart J 1999, 20:51-57. In this multicenter, randomized, double-blind trial, the oral treatment with nicorandil, in addition to antianginal treatment in patients with unstable angina, was shown to reduce transient myocardial ischemia and the incidence of ventricular and supraventricular arrhythmia.
69. 69 Kobayashi Y, Goto Y, Daikoku S, Itoh A, Miyazaki S, Ohshima S, et al.: Cardioprotecive effect of intravenous nicorandil in patients with successful reperfusion for acute myocardial infarction. Jpn Circ J 1998, 62:183-189.
70. 70 Shindo T, Yamada M, Isomoto S, Horio Y, Kurachi Y: SUR2 subtype (A and B)-dependent differential activation of the cloned ATP-sensitive K+ channels by pinacidil and nicorandil. Br J Pharmacol 1998, 124:985-991.
71. + channels and protects against simulated ischemia in rabbit myocytes. J Mol Cell Cardiol 1997, 29:1123-1130.
72. 72 Garlid KD, Paucek P, Yarov-Yarovoy V, Murray HN, Darbenzio RB, et al.: Cardioprotective effect of diazoxide and its interaction with mitochondrial ATP-sensitive K+ channels: possible mechanism of cardioprotection. Circ Res 1997, 81:1072-1082.
73. 73 Liu Y, Sato T, O'Rourke B, Marban E: Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection? Circulation 1998, 97:2463-2469. This study on rabbit ventricular myocytes demonstrates that diazoxide, as a selective opener of mitochondrial ATP-sensitive potassium channels, reduces markedly the rate of cell death in simulated ischemia, which might be a new basis for protection from ATP-sensitive potassium channel opening in preconditioning.
74. 74 Yabe K, Ishishita H, Tanonaka K, Takeo S: Pharmacologic preconditioning induced by beta-adrenergic stimulation is mediated by activation of protein kinase C. J Cardiovasc Pharmacol 1998, 32:962-968.
75. 75 Cleveland JC Jr, Meldrum DR, Rowland RT, Cain BS, Meng X, Gamboni-Robertson F, et al.: Ischemic preconditioning in human myocardium: protein kinase C mediates a permissive role for alpha adrenoreceptors. Am J Physiol 1997, 273:H902-H908.
76. 76 Tomai F, Crea F, Gaspardone A, Versaci F, Ghini AS, De Paulis R, et al.: Phentolamine prevents adaptation to ischemia during coronary angioplasty: role of alpha-adrenergic receptors in ischemic preconditioning. Circulation 1998, 96:2171-2177.
77. 77 Yoshida K, Kawamura S, Mizukami Y, Kitakaze M: Implication of protein kinase C-alpha, delta, and epsilon isoforms in ischemic preconditioning in rat hearts. J Biochem 1997, 122:506-511.
78. 78 Kawamura S, Yoshida K, Miura T, Mizukami Y, Matsuzaki M: Ischemic preconditioning translocates PKC-delta and -epsilon, which mediate functional protection in isolated rat hearts. Am J Physiol 1998, 275:H2266-H2271.
79. 79 Hu K, Duan D, Li GR, Nattel S: Protein kinase C activates ATP-sensitive K+ current in human and rabbit ventricular myocytes. Circ Res 1996, 78:492-498.
80. 80 Cain BS, Meldrum DR, Meng X, Shames BD, Banerjee A, Harken AH: Calcium preconditioning in human myocardium. Ann Thorac Surg 1998, 65:1065-1070.
81. + as a mediator of ischemic preconditioning. Circ Res 1997, 80:790-799.
82. 82 Miyamao M, Rodriguez MM, Camacho SA, Diamond I, Mochly-Rosen D, Figueredo VM: Activation of epsilon protein kinase C correlates with a cardioprotective effect of regular ethanol consumption. Proc Natl Acad Sci U S A 1998, 95:8262-8267.
83. 83 Verdouw PD, Gho BC, Dunucker DJ: Ischaemic preconditioning: is it clinically relevant? Eur Heart J 1995, 16:1169-1176.
84. 84 Miyamae M, Camacho SA, Zhou HZ, Diamond I, Figueredo VM: Alcohol consumption reduces ischemia-reperfusion injury by species-specific signaling in guinea pigs and rats. Am J Physiol 1998: 275:H50-H56.
85. 85 Schulz R, Post H, Vahlhaus C, Heusch G: Ischemic preconditioning in pigs: a graded phenomenon: its relation to adenosine and bradykinin. Circulation 1998, 98:1022-1029.
86. 86 Schwarz ER, Montino H, Fleischhauer J, Klues J, vom Dahl J, Hanrath P: Angiotensin II receptor antagonist EXP 3174 reduces infarct size comparable with enalaprilat and augments preconditioning in the pig heart. Cardiovasc Drugs Ther 1997, 11:687-695.
87. 87 Morris SD, Yellon DM: Angiotensin-converting enzyme inhibitors potentiate preconditioning through bradykinin B2 receptor activation in human heart. J Am Coll Cardiol 1997, 29:1599-1606.
88. 88 Schultz JJ, Hsu AK, Gross GJ: Ischemic preconditioning and morphine-induced cardioprotection involve the delta δ-opioid receptor in the intact rat heart. J Mol Cell Cardiol 1997, 29:2187-2195.
89. 89 Wang TL, Chang H, Hung CR, Tseng YZ: Morphine preconditioning attenuates neutrophil activation in rat models of myocardial infarction. Cardiovasc Res 1998, 40:557-563.
90. 90 Vogt AM, Htun P, Kluge A, Zimmermann R, Schaper W: Insulin-like growth factor-II delays myocardial infarction in experimental coronary artery occlusion. Cardiovasc Res 1997, 33:469-477.
91. 91 Htun P, Ito WD, Hoefer IE, Schaper J, Schaper W: Intramyocardial infusion of FGF-1 mimics ischemic preconditioning in pig myocardium. J Mol Cell Cardiol 1998, 30:867-877.
92. 92 Wang P, Gallagher KP, Downey JM, Cohen MV: Pretreatment with endothelin-1 mimics ischemic preconditioning against infarction in isolated rabbit hearts. J Mol Cell Cardiol 1996, 28:579-588.
93. 93 Garrat KN, Brady PA, Hassinger NL, Grill DE, Terzic A, Holmes DR Jr: Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999, 33:119-124. This study evaluates the hospital mortality in patients undergoing sulfonylurea therapy for diabetes after direct angioplasty for MI. Sulfonylurea drugs were independently associated with in-hospital mortality (odds ratio, 2.77).
94. 94 Cleveland JC Jr, Meldrum DR, Cain BS, Banerjee A, Harken AH: Oral sulfonylureahypoglycemic agents prevent ischemic preconditioning in human myocardium: two paradoxes revised. Circulation 1997, 96:29-32.
95. 95 Brady PA, Terzic A: The suffonylurea controversy: more questions from the heart. J Am Coll Cardiol 1998, 31:950-956.
96. 96 Elsässer A, Schlepper M, Klövekorn WP, Cai WJ, Zimmermann R, Müller KD, et al.: Hibernating myocardium: an incomplete adaptation to ischemia. Circulation 1997, 96:2920-2931.
97. 97 Schwarz ER, Schoendube FA, Kostin S, Schmiedtke N, Schulz G, Buell U, et al.: Prolonged myocardial hibernation exacerbates cardiomyocyte degeneration and impairs recovery of function after revascularization. J Am Coll Cardiol 1998, 31:1018-1026.
98. 98 The UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998, 352:837-853.